News Release

Study finds no increased cancer risk in rheumatology patients with history of malignancy taking DMARDS and TNF inhibitors

Reports and Proceedings

American College of Rheumatology

ATLANTA - New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, found no significant difference in cancer risk in patients with rheumatic disease and a history of malignancy taking biologic or targeted synthetic DMARDs compared to those treated with TNF inhibitors (Abstract #0267).


Patients with a history of cancer are routinely excluded from randomized controlled trials, so data on cancer risk is limited. This is particularly problematic in older adults with rheumatic diseases who are increasingly treated with biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs), despite a higher prevalence of comorbidities, including cancer. The researchers undertook this prospective observational study to investigate the occurrence and relative risk of incident cancer in patients with a history of malignancy treated with these medications.


The 352 patients in the study were drawn from BIOBADASER 3.0, a multicenter prospective registry for patients in Spain treated with biologic and targeted synthetic DMARDs. The new version of BIOBADASER was launched specifically to address the growing use of these drugs and changes in adverse events reporting.


The cohort were mostly women with rheumatoid arthritis (RA) and were included in the registry up to 2021. The majority of patients used TNF inhibitors and interleukin (IL)-17 inhibitors were used the least. Other medications included Janus kinase (JAK) inhibitors, IL-6 inhibitors, anti-CD20 antibodies and anti-CTLA-4 antibodies.


The researchers defined incident cancer as any cancer, including new primary cancers, local recurrences or metastases, that led to discontinuation of drug therapy. Among 352 patients, there were 32 incident cancers, with an overall rate of 27.1 events per 1,000 person years (PY), ranging from no events per 1,000 PY in the group taking IL-17 inhibitors to 51.7 events per 1,000 PY in the anti-CTLA-4 group.  Overall incidence did not differ significantly compared to TNF inhibitors, no matter whether patients were treated with JAK inhibitors, anti-CD20 antibodies, IL-6 or IL-17 inhibitors or anti-CTLA-4 antibodies. The rate of different types of cancer (one melanoma, 14 non-melanoma skin cancers and 17 solid tumors) also did not differ between the various treatment groups versus TNF inhibitor therapy.


Yet the study’s statistically insignificant results and high confidence intervals aren’t necessarily definitive, says Juan Molina-Collada, MD, a rheumatologist at Hospital General Universitario Gregorio Marañón in Madrid and the study’s lead author.


“We should say that we have not found an increased risk of cancer in this population, although we cannot exclude with our data a potential risk,” Dr. Molina-Collada says.


Dr. Molina-Collada also cites several limitations of the study, including selection bias, survivor bias and more-rigorous cancer screening of patients on immunosuppression therapies.


He also notes that long observational periods are needed to evaluate the risk of diseases such as cancer. In the study cohort, mean follow-up ranged from 11.5 to 23 months. Dr. Molina-Collada adds, “Medical national registries such as BIOBADSER have intrinsic limitations as to the quality of collected data, although external audits of the participating centers are routinely performed.”


Yet he points out that because this large study did not find an increase in the overall occurrence of cancer in patients with rheumatic diseases and prior cancer, the “results are reassuring on the pattern of use of these therapies.” He notes that “this is the first study, to our knowledge, to provide safety data on the use of targeted synthetic DMARDs or anti-IL-17 inhibitors in patients with a history of cancer.”



About ACR Convergence

ACR Convergence, the annual meeting of the American College of Rheumatology, is where rheumatology meets to collaborate, celebrate, congregate, and learn. With more than 320 sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, business education and interactive discussions to improve patient care. For more information about the meeting, visit, or join the conversation on Twitter by following the official hashtag (#ACR22).

About the American College of Rheumatology

Founded in 1934, the American College of Rheumatology (ACR) is a not-for-profit, professional association committed to advancing the specialty of rheumatology that serves nearly 8,500 physicians, health professionals, and scientists worldwide. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases. For more information, visit   

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.